R&D News | pharmaphorum

News

Sanofi’s oral BTK programme gets back on track

Sanofi has chalked up another win in a clinical trial of its oral BTK inhibitor rilzabrutinib, setting up regulatory filings in its first indication – rare disorder immune

News

Shakeup at BenevolentAI continues with job, programme cuts

BenevolentAI is embarking on another round of job losses, closing its US office, and shelving its software-as-a-service business to extend its cash reserves into the third

News

With $75m cash injection, SynOx plans ph3 rare tumour trial

Ireland’s SynOx Therapeutics has completed a second-round financing, raising $75 million, as it prepares to take its drug for tenosynovial giant cell tumour (TGCT) into ph

News

Ipsen signs $1.8bn RNA drug alliance with Skyhawk

Ipsen has expanded its R&D pipeline once again, agreeing a $1.8 billion alliance with Skyhawk Therapeutics focused on the development of RNA-targeting therapies for ra

News

Hyundai Bio plans trials of antiviral for dengue fever

South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral

News

Cerevel Parkinson’s data adds lustre to AbbVie acquisition

Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its blockbuster potential and no doubt delighting AbbVie, wh

Sanofi’s oral BTK programme gets back on track

Shakeup at BenevolentAI continues with job, programme cuts

With $75m cash injection, SynOx plans ph3 rare tumour trial

Ipsen signs $1.8bn RNA drug alliance with Skyhawk

Hyundai Bio plans trials of antiviral for dengue fever

Cerevel Parkinson’s data adds lustre to AbbVie acquisition

Bayer hits "turning point" in recovery plan, says CEO

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks